



1642

<b>TRANSMITTAL LETTER</b>		Case No. 10716/15
Filing Date October 31, 2000	Examiner Gary B. Nickol, Ph.D.	Group Art Unit 1642
Applicant No. 09/703,350		
Inventor(s) Gerritsen et al.		
Title of Invention DIFFERENTIALLY EXPRESSED GENES INVOLVED IN ANGIOGENESIS, THE POLYPEPTIDES THEREBY, AND METHODS OF USING THE SAME		

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is Substitute computer readable form copy of the Sequence Listing. Substitute paper copy of the Sequence Listing. Amendment. Statement. copy of NOTICE TO COMPLY and return-receipt postcard.

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.
- ☐ Petition for a \_\_\_\_\_ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra
Total		Minus		
Indep.		Minus		
First Presentation of Multiple Dep. Claim				

Small Entity	
Rate	Add'l Fee
x \$9=	
x 42=	
+\$140=	
Total add'l fee	\$

Other Than Small Entity	
Rate	Add'l Fee
x \$18=	
x \$84=	
+\$280=	
Total add'l fee	\$

- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$\_\_\_\_\_. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$\_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,  
  
Gregory M. Zycki, Ph.D.  
Registration No. 48,492  
Agent for Applicant

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, ILLINOIS 60610  
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on May 22, 2002.

Date: 5/22/02 Signature:

RECEIVED  
JUN 05 2002  
TECH. CENTER 1600/2900

I hereby certify that this correspondence is deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on May 22, 2002.

Gregory M. Zinkl, Ph.D.

Name of applicant, assignee or  
Registered Representative

Signature

Case No. 10716/15



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Gerritsen, et al..

Serial No.: 09/703,350

Filed: October 31, 2000

For: DIFFERENTIALLY EXPRESSED GENES  
INVOLVED IN ANGIOGENESIS, THE  
POLYPEPTIDES THEREBY, AND METHODS OF  
USING THE SAME

Attention: Manager,  
Application Branch

TECH CENTER 1600/2900

JUN 05 2002

RECEIVED

STATEMENT ACCORDING TO 37 C.F.R. § 1.821(f)

**BOX SEQUENCE LISTING**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Submitted herewith is a sequence listing as part of the above-captioned patent application. Applicants' representative states that the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are the same.

Applicants' representative hereby verifies that the information on the accompanying diskette is identical to the written sequence listing. The enclosed sequence listing does not include any new matter that goes beyond the disclosure in the captioned application as filed.

Respectfully submitted,

Dated: 5/22/02

Gregory M. Zinkl  
Gregory M. Zinkl, Ph.D.  
Registration No. 48,492  
Agent for Applicants

BRINKS HOFER GILSON & LIONE  
P.O. BOX 10395  
CHICAGO, IL 60610  
(312) 321-4780



Application No. 09/703350

RECEIVED  
JUN 05 2002  
TECHNICAL CENTER  
600/2900

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**